RxDoctor Payments Data

Kevin Nickell, MD

Urology · Houston, TXNPI 1053388785

Payments from drug & device makers

$22,152in general payments, 2019–2025

Across 481 payments — averaging $46.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • HMU Consumables, LLC$9K
  • Boston Scientific$2K
  • Pfizer$996
  • Coloplast$977
  • Sumitomo Pharma America, Inc.$742
  • Astellas Pharma US Inc$737
  • plus $8K from 45 others

What the payments were for

  • Food & beverage$13,23472%
  • Education$720%
  • Other$5,14328%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,152 in reported general payments places this provider in the 80th percentile of 878 urology providers in Texas.

See all urology providers in Texas

Medicare billing

Part B allowed, 2024
$481,265
Medicare patients
914
Services billed
26,102

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide54$920,168
ErleadaApalutamide19$285,029
Thiola EcTiopronin11$145,779
GemtesaVibegron180$141,773
MyrbetriqMirabegron85$62,564
Abiraterone Acetate16$29,626
AveedTestosterone Undecanoate14$25,737
Tamsulosin Hcl1,697$25,687
Finasteride1,214$18,186
Solifenacin Succinate274$14,348
Testosterone87$12,816
Potassium Citrate ErPotassium Citrate57$8,991
Silodosin68$7,402
Testosterone Cypionate75$4,591
Trospium Chloride ErTrospium Chloride20$4,069

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$737$982,733139 claims
Johnson & JohnsonErleada$701$285,02919 claims
Sumitomo Pharma America, Inc.Gemtesa$742$141,773180 claims
Endo Pharmaceuticals Inc.Aveed$418$25,73714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 878 urology providers in Texas.

Other urology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →